The recent translational Phase 2 Ghrelin in Coma (GRECO) trial showed safety and potential effectiveness in enhancing neurological outcome of intravenous treatment with acyl-ghrelin during the first 7 days after cardiac arrest.5 Results showed a statistically significant reduction of neuron-specific enolase values at Day 1 after cardiac arrest in the intervention group, as well as a non-significant shift towards a better neurological outcome at 6 months that was consistent over all cerebral performance categories (CPCs) and subgroups. This evidence concerns the gene ENO2 and cardiac arrest.